2020 Year in Review - Breast Cancer
2020 Year in Review - Breast Cancer | January 25, 2021
Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.
2020 Year in Review - Breast Cancer | January 25, 2021
In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose.
2020 Year in Review - Breast Cancer | January 25, 2021
In addition to the significant benefit observed in the MONARCH 2 study across first- and second-line treatment, marked effects were observed in patients with less encouraging prognostic indicators.
2020 Year in Review - Breast Cancer | January 25, 2021
Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative, endocrine-sensitive, advanced breast cancer.
2020 Year in Review - Breast Cancer | January 25, 2021
Across the MONALEESA-2, -3, and -7 clinical trials, first-line treatment with endocrine therapy and ribociclib mitigated negative effects on quality of life, global health scores, pain, and emotional functioning.
2020 Year in Review - Breast Cancer | January 25, 2021
While progression-free survival was similar, overall survival was better in CDK4/6 inhibitor combinations as first-line therapy followed by everolimus combinations and chemotherapy.
2020 Year in Review - Breast Cancer | January 25, 2021
In a range of groups with PIK3CA alterations, recent findings demonstrate a clear and consistent clinical benefit of alpelisib when combined with fulvestrant, which was detected in circulating tumor DNA by next-generation sequencing.
2020 Year in Review - Breast Cancer | January 25, 2021
For patients with hormone receptor–positive, HER2-negative metastatic breast cancer, response rates for platinum-based chemotherapy were lower than historically observed in patients with triple-negative breast cancer, associated with poor outcomes.
2020 Year in Review - Breast Cancer | January 25, 2021
The majority of patients with metastatic breast cancer receiving treatment with CDK4/6 inhibitors had progression-free survival, behaving similarly when used as first-line therapy or after adjuvant hormonal therapy.
© 2009-2021 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512